aTyr Pharma Doses First Patient In Long-Term Safety Extension Study Of Resolaris™ for Treatment of Adult Patients with FSHD
September 10, 2015Resolaris™ is the first Physiocrine-based therapeutic under investigation for any disease and is based on a naturally occurring protein identified by aTyr Pharma. Trails in additional indications are expected to initiate later this year.
More »
Marinus Pharmaceuticals Announces Positive End-of-Phase 2 Meeting With FDA for Ganaxolone in Focal Onset Seizures
September 9, 2015The FDA is in agreement with Marinus on its planned path to support registration of ganaxolone for adjunctive treatment of focal onset seizures, which includes a single additional Phase 3 registration study to assess the efficacy and safety.
More »
Tandem Diabetes Care Announces FDA Approval of t:slim G4 Insulin Pump with CGM Integration
September 9, 2015The t:slim G4™ Insulin Pump is the first and only touch-screen pump with CGM integration. It combines features of the highly ranked t:slim® Insulin Pump and Dexcom G4® PLATINUM CGM System into a single device that can help simplify therapy management.
More »